RNAZ
Transcode Therapeutics Inc
NASDAQ: RNAZ · HEALTHCARE · BIOTECHNOLOGY
$8.01
-4.64% today
Updated 2026-04-30
Market cap
$7.75M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-52.59
Dividend yield
—
52W range
$6 – $22
Volume
0.0M
Transcode Therapeutics Inc (RNAZ) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | $214646.00 | $216743.00 | $1.06M | $22.94M | $7.59M | $5.17M | $7.29M |
| Cash & equivalents | $212979.00 | $204471.00 | $828016.00 | $20.83M | $4.97M | $2.77M | $5.81M |
| Current assets | $214646.00 | $204471.00 | $831215.00 | $22.73M | $7.38M | $4.46M | $7.09M |
| Total liabilities | $718613.00 | $1.31M | $4.46M | $2.53M | $4.35M | $3.53M | $9.31M |
| Current liabilities | $117682.00 | $62942.00 | $404862.00 | $2.53M | $4.35M | $3.49M | $2.77M |
| Long-term debt | — | $927810.00 | $2.09M | — | — | — | — |
| Shareholder equity | $-503967.00 | $-1.10M | $-3.41M | $20.40M | $3.24M | $1.64M | $-2.02M |
| Retained earnings | $-510777.00 | $-1.12M | $-3.46M | $-10.31M | $-27.87M | $-46.42M | $-63.20M |
| Accounts receivable | — | — | — | — | $360229.00 | — | — |
| Inventory | — | — | — | — | $554330.00 | — | — |
| Goodwill | — | — | — | — | — | — | — |